Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254


Cardiovascular models for personalised medicine: Where now and where next?

Hose DR, Lawford PV, Huberts W, Hellevik LR, Omholt SW, van de Vosse FN.

Med Eng Phys. 2019 Oct;72:38-48. doi: 10.1016/j.medengphy.2019.08.007.


Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.


Estimation of valvular resistance of segmented aortic valves using computational fluid dynamics.

Hoeijmakers MJMM, Silva Soto DA, Waechter-Stehle I, Kasztelnik M, Weese J, Hose DR, de Vosse FNV.

J Biomech. 2019 Sep 20;94:49-58. doi: 10.1016/j.jbiomech.2019.07.010. Epub 2019 Jul 17.


Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.

Grab AL, Seckinger A, Horn P, Hose D, Cavalcanti-Adam EA.

Acta Biomater. 2019 Sep 15;96:258-270. doi: 10.1016/j.actbio.2019.07.018. Epub 2019 Jul 11.


Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells.

Darche FF, Rivinius R, Köllensperger E, Leimer U, Germann G, Seckinger A, Hose D, Schröter J, Bruehl C, Draguhn A, Gabriel R, Schmidt M, Koenen M, Thomas D, Katus HA, Schweizer PA.

Life Sci. 2019 Sep 1;232:116620. doi: 10.1016/j.lfs.2019.116620. Epub 2019 Jul 7.


Kinome expression profiling to target new therapeutic avenues in multiple myeloma.

de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J.

Haematologica. 2019 Jul 9. pii: haematol.2018.208306. doi: 10.3324/haematol.2018.208306. [Epub ahead of print]


Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.


Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.


A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI.

Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25.


Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8. No abstract available.


Construction of lumped-parameter cardiovascular models using the CellML language.

Shi Y, Lawford P, Hose DR.

J Med Eng Technol. 2018 Oct;42(7):525-531. doi: 10.1080/03091902.2019.1576792. Epub 2019 Feb 18.


Patient-specific non-invasive estimation of pressure gradient across aortic coarctation using magnetic resonance imaging.

Shi Y, Valverde I, Lawford PV, Beerbaum P, Hose DR.

J Cardiol. 2019 Jun;73(6):544-552. doi: 10.1016/j.jjcc.2018.12.016. Epub 2019 Jan 29.


Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.


Personalised Fractional Flow Reserve: Novel Concept to Optimise Myocardial Revascularization.

Gosling RC, Morris PD, Lawford PV, Hose DR, Gunn JP.

EuroIntervention. 2018 Dec 18. pii: EIJ-D-18-00668. doi: 10.4244/EIJ-D-18-00668. [Epub ahead of print]


Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

Danhof S, Strifler S, Hose D, Kortüm M, Bittrich M, Hefner J, Einsele H, Knop S, Schreder M.

J Cancer Res Clin Oncol. 2019 Mar;145(3):561-571. doi: 10.1007/s00432-018-2807-1. Epub 2018 Dec 5.


BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, Ceballos P, Cartron G, Hose D, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2019 May;96(3):209-214. doi: 10.1002/cyto.b.21730. Epub 2018 Nov 12.


Characterization of small fiber pathology in a mouse model of Fabry disease.

Hofmann L, Hose D, Grießhammer A, Blum R, Döring F, Dib-Hajj S, Waxman S, Sommer C, Wischmeyer E, Üçeyler N.

Elife. 2018 Oct 17;7. pii: e39300. doi: 10.7554/eLife.39300.


Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.


PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.


Predictive Physiological Modeling of Percutaneous Coronary Intervention - Is Virtual Treatment Planning the Future?

Gosling RC, Morris PD, Lawford PV, Hose DR, Gunn JP.

Front Physiol. 2018 Aug 13;9:1107. doi: 10.3389/fphys.2018.01107. eCollection 2018. Review.


CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.


Increased Serpina3n release into circulation during glucocorticoid-mediated muscle atrophy.

Gueugneau M, d'Hose D, Barbé C, de Barsy M, Lause P, Maiter D, Bindels LB, Delzenne NM, Schaeffer L, Gangloff YG, Chambon C, Coudy-Gandilhon C, Béchet D, Thissen JP.

J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):929-946. doi: 10.1002/jcsm.12315. Epub 2018 Jul 10.


Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.


Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.


Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.

Tsiklauri L, Werner J, Kampschulte M, Frommer KW, Berninger L, Irrgang M, Glenske K, Hose D, El Khassawna T, Pons-Kühnemann J, Rehart S, Wenisch S, Müller-Ladner U, Neumann E.

Osteoarthritis Cartilage. 2018 Sep;26(9):1225-1235. doi: 10.1016/j.joca.2018.06.001. Epub 2018 Jun 14.


RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.

Seckinger A, Bähr-Ivacevic T, Benes V, Hose D.

Methods Mol Biol. 2018;1792:97-115. doi: 10.1007/978-1-4939-7865-6_7.


Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.


Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.


An Asymmetric Wall-Thickening Pattern Predicts Response to Cardiac Resynchronization Therapy.

Warriner DR, Jackson T, Zacur E, Sammut E, Sheridan P, Hose DR, Lawford P, Razavi R, Niederer SA, Rinaldi CA, Lamata P.

JACC Cardiovasc Imaging. 2018 Oct;11(10):1545-1546. doi: 10.1016/j.jcmg.2018.01.022. Epub 2018 Mar 14. No abstract available.


Virtual Coronary Intervention: A Treatment Planning Tool Based Upon the Angiogram.

Gosling RC, Morris PD, Silva Soto DA, Lawford PV, Hose DR, Gunn JP.

JACC Cardiovasc Imaging. 2019 May;12(5):865-872. doi: 10.1016/j.jcmg.2018.01.019. Epub 2018 Mar 14.


DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.


Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S.

Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. No abstract available.


The impact of Objective Mathematical Analysis during Fractional Flow Reserve measurement: results from the OMA-FFR study.

Sciola MI, Morris PD, Gosling R, Lawford PV, Hose DR, Gunn JP.

EuroIntervention. 2018 Oct 20;14(8):935-941. doi: 10.4244/EIJ-D-17-00826.


Quantification of plasma cell dynamics using mathematical modelling.

Mohr M, Hose D, Seckinger A, Marciniak-Czochra A.

R Soc Open Sci. 2018 Jan 24;5(1):170759. doi: 10.1098/rsos.170759. eCollection 2018 Jan.


Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.


Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.


From Bench to Bedside: A View on Bioinformatics Pipelines.

Flores B, Hose D, Seckinger A, Knaup P, Ganzinger M.

Stud Health Technol Inform. 2017;245:375-378.


Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.


A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model.

Schulze F, Malhan D, El Khassawna T, Heiss C, Seckinger A, Hose D, Rösen-Wolff A.

BMC Genomics. 2017 Dec 19;18(1):975. doi: 10.1186/s12864-017-4356-4.


CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, Boireau S, Seckinger A, Hose D, Klein B, Moreaux J.

Oncotarget. 2017 Oct 30;8(58):98931-98944. doi: 10.18632/oncotarget.22131. eCollection 2017 Nov 17.


Fast Virtual Fractional Flow Reserve Based Upon Steady-State Computational Fluid Dynamics Analysis: Results From the VIRTU-Fast Study.

Morris PD, Silva Soto DA, Feher JFA, Rafiroiu D, Lungu A, Varma S, Lawford PV, Hose DR, Gunn JP.

JACC Basic Transl Sci. 2017 Aug 28;2(4):434-446. doi: 10.1016/j.jacbts.2017.04.003. eCollection 2017 Aug.


Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.


Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.


A cell-based mechanical model of coronary artery tunica media.

Melnikova NB, Svitenkov AI, Hose DR, Hoekstra AG.

J R Soc Interface. 2017 Jul;14(132). pii: 20170028. doi: 10.1098/rsif.2017.0028.


Osteocyte Regulation of Receptor Activator of NF-κB Ligand/Osteoprotegerin in a Sheep Model of Osteoporosis.

El Khassawna T, Merboth F, Malhan D, Böcker W, Daghma DES, Stoetzel S, Kern S, Hassan F, Rosenbaum D, Langenstein J, Bauer N, Schlagenhauf A, Rösen-Wolff A, Schulze F, Rupp M, Hose D, Secklinger A, Ignatius A, Wilke HJ, Lips KS, Heiss C.

Am J Pathol. 2017 Aug;187(8):1686-1699. doi: 10.1016/j.ajpath.2017.04.005. Epub 2017 Jun 12.


Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.

Kruppke B, Hose D, Schnettler R, Seckinger A, Rößler S, Hanke T, Heinemann S.

J Biomed Mater Res B Appl Biomater. 2018 Apr;106(3):1165-1173. doi: 10.1002/jbm.b.33931. Epub 2017 May 29.


Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.


Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.


Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.


Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.

Supplemental Content

Support Center